Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity

Autores
Zingales, Bianca; Miles, Michael A.; Moraes, Carolina B.; Luquetti, Alejandro; Guhl, Felipe; Schijman, Alejandro Gabriel; Ribeiro, Isabela
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
Fil: Zingales, Bianca. Universidade de São Paulo. Instituto de Química; Brasil
Fil: Miles, Michael A.. London School of Hygiene and Tropical Medicine. Faculty of Infectious and Tropical Diseases; Reino Unido
Fil: Moraes, Carolina B.. Centro Nacional de Pesquisa em Energias e Matérias. Laboratório Nacional de Biociências; Brasil
Fil: Luquetti, Alejandro. Universidade Federal de Goiás. Hospital das Clínicas; Brasil
Fil: Guhl, Felipe. Universidad de los Andes. Facultad de Ciencias. Centro de Investigaciones en Microbiología y Parasitología Tropical; Colombia
Fil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular; Argentina
Fil: Ribeiro, Isabela. Drugs for Neglected Disease initiative; Suiza
Materia
In vitro drug screening
T. cruzi genetic diversity
Guidelines
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/4003
Acceder
id CONICETDig_8858fed4422ccae099cc647573955093
oai_identifier_str oai:ri.conicet.gov.ar:11336/4003
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversityZingales, BiancaMiles, Michael A.Moraes, Carolina B.Luquetti, AlejandroGuhl, FelipeSchijman, Alejandro GabrielRibeiro, IsabelaIn vitro drug screeningT. cruzi genetic diversityGuidelineshttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3https://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.Fil: Zingales, Bianca. Universidade de São Paulo. Instituto de Química; BrasilFil: Miles, Michael A.. London School of Hygiene and Tropical Medicine. Faculty of Infectious and Tropical Diseases; Reino UnidoFil: Moraes, Carolina B.. Centro Nacional de Pesquisa em Energias e Matérias. Laboratório Nacional de Biociências; BrasilFil: Luquetti, Alejandro. Universidade Federal de Goiás. Hospital das Clínicas; BrasilFil: Guhl, Felipe. Universidad de los Andes. Facultad de Ciencias. Centro de Investigaciones en Microbiología y Parasitología Tropical; ColombiaFil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular; ArgentinaFil: Ribeiro, Isabela. Drugs for Neglected Disease initiative; SuizaFundacao Oswaldo Cruz2014-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/4003Zingales, Bianca; Miles, Michael A.; Moraes, Carolina B.; Luquetti, Alejandro; Guhl, Felipe; et al.; Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity; Fundacao Oswaldo Cruz; Memórias Do Instituto Oswaldo Cruz; 109; 6; 9-2014; 828-8330074-02761678-8060enginfo:eu-repo/semantics/altIdentifier/url/http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762014000600828&lng=en&nrm=iso&tlng=eninfo:eu-repo/semantics/altIdentifier/doi/10.1590/0074-0276140156info:eu-repo/semantics/altIdentifier/issn/0074-0276info:eu-repo/semantics/altIdentifier/url/http://memorias.ioc.fiocruz.br/issues/past-issues/item/1719-0156_drug-discovery-for-chagas-disease-should-consider-trypanosoma-cruzi-strain-diversityinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-17T10:44:08Zoai:ri.conicet.gov.ar:11336/4003instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-17 10:44:08.988CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
title Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
spellingShingle Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
Zingales, Bianca
In vitro drug screening
T. cruzi genetic diversity
Guidelines
title_short Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
title_full Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
title_fullStr Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
title_full_unstemmed Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
title_sort Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
dc.creator.none.fl_str_mv Zingales, Bianca
Miles, Michael A.
Moraes, Carolina B.
Luquetti, Alejandro
Guhl, Felipe
Schijman, Alejandro Gabriel
Ribeiro, Isabela
author Zingales, Bianca
author_facet Zingales, Bianca
Miles, Michael A.
Moraes, Carolina B.
Luquetti, Alejandro
Guhl, Felipe
Schijman, Alejandro Gabriel
Ribeiro, Isabela
author_role author
author2 Miles, Michael A.
Moraes, Carolina B.
Luquetti, Alejandro
Guhl, Felipe
Schijman, Alejandro Gabriel
Ribeiro, Isabela
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv In vitro drug screening
T. cruzi genetic diversity
Guidelines
topic In vitro drug screening
T. cruzi genetic diversity
Guidelines
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
Fil: Zingales, Bianca. Universidade de São Paulo. Instituto de Química; Brasil
Fil: Miles, Michael A.. London School of Hygiene and Tropical Medicine. Faculty of Infectious and Tropical Diseases; Reino Unido
Fil: Moraes, Carolina B.. Centro Nacional de Pesquisa em Energias e Matérias. Laboratório Nacional de Biociências; Brasil
Fil: Luquetti, Alejandro. Universidade Federal de Goiás. Hospital das Clínicas; Brasil
Fil: Guhl, Felipe. Universidad de los Andes. Facultad de Ciencias. Centro de Investigaciones en Microbiología y Parasitología Tropical; Colombia
Fil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular; Argentina
Fil: Ribeiro, Isabela. Drugs for Neglected Disease initiative; Suiza
description This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
publishDate 2014
dc.date.none.fl_str_mv 2014-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/4003
Zingales, Bianca; Miles, Michael A.; Moraes, Carolina B.; Luquetti, Alejandro; Guhl, Felipe; et al.; Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity; Fundacao Oswaldo Cruz; Memórias Do Instituto Oswaldo Cruz; 109; 6; 9-2014; 828-833
0074-0276
1678-8060
url http://hdl.handle.net/11336/4003
identifier_str_mv Zingales, Bianca; Miles, Michael A.; Moraes, Carolina B.; Luquetti, Alejandro; Guhl, Felipe; et al.; Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity; Fundacao Oswaldo Cruz; Memórias Do Instituto Oswaldo Cruz; 109; 6; 9-2014; 828-833
0074-0276
1678-8060
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762014000600828&lng=en&nrm=iso&tlng=en
info:eu-repo/semantics/altIdentifier/doi/10.1590/0074-0276140156
info:eu-repo/semantics/altIdentifier/issn/0074-0276
info:eu-repo/semantics/altIdentifier/url/http://memorias.ioc.fiocruz.br/issues/past-issues/item/1719-0156_drug-discovery-for-chagas-disease-should-consider-trypanosoma-cruzi-strain-diversity
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Fundacao Oswaldo Cruz
publisher.none.fl_str_mv Fundacao Oswaldo Cruz
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1843605961364733952
score 13.001348

Publicaciones similares